Cisplatin: continuous versus bolus

J Pediatr Hematol Oncol. 2006 Feb;28(2):60-1. doi: 10.1097/01.mph.0000199584.91302.e5.
No abstract available

Publication types

  • Comment
  • Comparative Study

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / pharmacokinetics
  • Child
  • Cisplatin / administration & dosage*
  • Cisplatin / adverse effects
  • Cisplatin / blood
  • Cisplatin / pharmacokinetics
  • Endodermal Sinus Tumor / complications
  • Endodermal Sinus Tumor / drug therapy
  • Half-Life
  • Hearing Loss, Sensorineural / chemically induced
  • Hearing Loss, Sensorineural / prevention & control*
  • Humans
  • Infusions, Intravenous
  • Injections, Intravenous
  • Neoplasms, Germ Cell and Embryonal / complications
  • Neoplasms, Germ Cell and Embryonal / drug therapy
  • Protein Binding
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Cisplatin